Capitalstars Updates: Top Corporate News :- 29 Jan 2018

Top Headlines Of The Day :- 29 Jan 2018

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
DLF is looking to launch QIP of shares by April, 2018
Idea Cellular seeks government approval for raising FDI limit to 100%

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
DMart rallies 5% after announcing Q3FY18 results. In Q3FY18, its revenue grew by 22.6% yoy to Rs4, 095cr. EBITDA came in at Rs422cr, up 46.3% yoy . EBITDA margin expanded by 167bps yoy to 12.3% due to an improvement in sales mix and efficiency of centralized procurement. Adjusted PAT increased by 65.8% yoy to Rs252cr.
Board has also approved acquisition of 50.8% paid-up share capital of Avenue E-Commerce Limited for Rs49.2cr. Post-acquisition it will become wholly owned subsidiary. Heavy discounts to attract price sensitive customers and losses of the e-commerce entity will offset the margin gains.

Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Cipla, Aurobindo and Strides Shasun have received final approval for their Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the USFDA. This is a generic version of Gilead Sciences' Viread Tablets, 300mg which is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults. The final approval means that product is available for immediate commercialization in the US.
Viread 300mg tablets had annual US sales of approximately $725-750mn as per IMS Health. An orange book search on USFDA website indicates that Aurobindo, Cipla, Teva, Macleods Pharmaceuticals and Strides Shasun, all have received approval for this drug on January 26, 2018. Approval for five different filers on the same day is likely to see competition for the Viread 300mg tablets.

Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
Havells is setting-up a new facility at Ghiloth, Neemrana, Rajasthan to manufacture consumer durables, as per the BSE filing. The total estimated cost for the project is Rs360cr (ex-land cost, as the company already owns the land), spread over a period of 3 years. The total investment will be funded through a mix of internal accruals and borrowings. Company expects to start the production from Q3FY19E.
For this investment, the company will be entitled to investment subsidy under the M-SIPS (Modified Special Incentive Package Scheme) introduced by MEITY and also for various tax/ levies and other benefits from the State Government of Rajasthan.

DLF is looking to launch QIP of shares by April, 2018
DLF is looking to launch its qualified institutional placement (QIP) of shares by April 2018, according to a media report.
DLF has already received approval from shareholders to sell 173-million equity shares, which will be determined by the formula laid down by the market regulator Securities and Exchange Board of India. The company may raise Rs4500-5000cr from the QIP.

Idea Cellular seeks government approval for raising FDI limit to 100%
Telecom operator Idea Cellular has made an application to the DIPP (Department of Industrial Policy and Promotion) for raising the FDI limit in Idea to 100%. Foreign investors holdings in Idea Cellular stood at ~27% stake as on December 2017. While 100% FDI is allowed in telecom companies, investments under the automatic route are allowed up to 49%.
At present, Idea Cellular is in the process of merging its telecom business with the Indian unit of Vodafone. As per latest industry data from Trai, Idea and Vodafone jointly have 40.5cr mobile subscribers. This would potentially give the joint entity the largest subscriber base in the Indian telecom segment. Vodafone is expected to hold around 47.5% stake in the merged entity and rest will be owned by Idea and its promoter Aditya Birla Group.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Birla MF Co-CIO Patil sees low teens 2018 growth for Nifty, likes auto, consumer durables, telecom:- 27 Jan 2018

Considering the government’s long-term vision, and the trend set through earlier budgets, the focus of the upcoming Union Budget is likely to remain largely on infrastructure and the rural economy, believes Mahesh Patil, Co-Chief Investment Officer-equities at Aditya Birla Sun Life Mutual Fund.

In an exclusive interview to Moneycontrol, Patil said that investors should not expect a repeat of 2017 in terms of returns, since the Nifty returned as much as 29 percent in the year. It is unlikely to happen again in 2018

We saw a good run up in 2017. How do you see markets panning out in 2018?

2018, as we step forward into this new calendar year, things are looking much better. A lot of things have fallen into place. Last year, we went through ups and downs. The economy took kind of a beating, but the gains of all the reforms would start to unfold and we are expecting a pretty good recovery back in corporate earnings.

Global outlook continues to remain fairly stronger than it was after the global financial crisis. So, all these tailwinds should continue to favour the markets. Since we did very well last year, the return expectations would probably have to be moderated down now because we are starting from a higher valuation level and to that extent, the market returns this calendar year would probably be muted compared to last year. But still, our view is that returns should be fairly good for investors to look positively at equities compared to any other asset class.

According to your presentation GDP, growth will be more than 7 percent in FY19. Is that achievable?

Yes, it is fairly achievable because the growth was pulled down because of reforms. We are seeing some recovery in capital expenditure, at least private sector capex will slowly start to pick up, though not in a big way. But at least the lower end will and rural consumption is moving up. Global growth is also fairly strong. So, even the net exports should be fairly good. So 7 percent GDP growth, considering all these factors, should quite be possible.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: Top Corporate News :- 25 Jan 2018

Top Headlines Of The Day:- 25 Jan 2018

Dr. Reddy's slumps 3% on unimpressive Oct-Dec earnings

Biocon slumps as Oct-Dec consol PAT below estimate

NCC’s Board to meet on January 30 to approve QIP issue price

Glenmark reports encouraging clinical trial data on GBR 1302

Dr. Reddy’s Bachupally plant completes successful re-inspection by German regulator

Dr. Reddy's slumps 3% on unimpressive Oct-Dec earnings
Shares of Dr. Reddy's Laboratories slumped nearly 3% as investors were unimpressed by the company's earnings for the December quarter.
The drug maker reported a consolidated net profit of Rs290cr, sharply below analysts' estimate of Rs350cr. Continued rise in pricing pressure and lack of new product launches in the US during the quarter weighed on the company's operating margin, which contracted 250bps on year to 21.2%.

Biocon slumps as Oct-Dec consol PAT below estimate
Shares of Biocon slumped over 4% after the company reported a 46.4% on-year fall in consolidated net profit for the December quarter at Rs91.9cr, below analysts' estimate.
Revenue from operations for the quarter was at Rs1058cr, against Rs1044cr a year ago. Sales in Oct-Dec were in line with estimates.

NCC’s Board to meet on January 30 to approve QIP issue price
NCC stock is up 3.3% on the back of news that the Board of Directors of NCC will meet on January 30, 2018, to consider and approve the issue price, including a discount for the equity shares to be allotted to the qualified institutional buyers in the issue.
NCC Ltd is one of the largest Indian construction companies in terms of revenue. The company’s order book was worth Rs28,109cr as of October 2017. The revenues of the company were impacted by GST implementation. We expect the company to report revenue CAGR of 3% over FY17-19E. We estimate the company’s margin to rise by 70bps on the back of cost optimization and timely execution of projects. We expect the company to report PAT CAGR of 3% over FY17-19E.

Glenmark reports encouraging clinical trial data on GBR 1302
Glenmark Pharma has reported positive clinical trial data on its phase 1 molecule GBR 1302. GBR 1302 is a potential drug candidate for Breast Cancer and Gastric Cancer.
The company has indicated that the preliminary data for GBR 1302 tells about the spikes in peripheral blood cytokines and a drop in T cell levels suggesting the potential for T cell activation.
The company has said that it is encouraged by these initial findings and look forward to continuing the studies.  GBR 1302 is Glenmark’s lead immuno-oncology agent based on the proprietary BEAT® bispecific antibody engineering platform.

Dr. Reddy’s Bachupally plant completes successful re-inspection by German regulator
Dr. Reddy’s has announced that the German drug regulator has carried out re-inspection of its Bachupally formulations plant (unit 2). The company has successfully completed this re-inspection as its subsidiary Betapharm has received a communication from the regulator that it can now start dispatching products to Europe from this plant.
The status of the EU GMP non-compliance is also to be removed from its plant by the Government of Upper Bavaria.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: Top Corporate News:- 24 Jan 2018

Top Headlines Of The Day:- 24 Jan 2018

RBL Bank falls 4% as asset quality worsens in Oct-Dec

Ashok Leyland bags order for 1,200 trucks from VRL Logistics

Bharti Airtel gets approval for acquiring operations of Millicom in Rwanda

Eveready to form JV with Indonesia based company for FMCG products

Bank of Baroda may float $1bn QIP soon

RBL Bank falls 4% as asset quality worsens in Oct-Dec
RBL Bank stock fell over 4% after the company reported an increase in bad loans in Oct-Dec, and net profit missed estimates.
For Q3FY18, RBL Bank’s NII improved by 45% yoy to Rs467cr against Rs322cr in Q3FY17.
The NIMs for Q3FY18 stood at 3.89%, which improved by 15bps qoq. The bank’s net profit was below estimates, improvement of 27.9% yoy to Rs165cr against Rs129cr.
Its GNPA for Q3FY18 stood at 1.56% against 1.44% qoq, which has increased by 12bps. NNPA for the quarter came at 0.97% against 0.78% qoq.
The advances for the quarter came at Rs36, 890cr, up 38% yoy and 10% qoq.

Ashok Leyland bags order for 1,200 trucks from VRL Logistics
Ashok Leyland Limited (ALL), one of the largest commercial vehicle (CV) manufacturers in India, bagged an order for 1,200 trucks from VRL Logistics Limited (VRL). The order for 1,200 trucks is for two models – “AL 3123” and “AL 3723”, for 600 units each. ALL released this to the stock exchanges on January 24, 2018. The order amounts to Rs350cr. VRL is a key client for ALL since the former sources 80% of its CV requirement from the latter. 
ALL is the third largest manufacturer of commercial vehicles (trucks, buses, tippers, trailers and defence vehicles) in India with ~18% market share. The company is also engaged in the manufacturing and selling of engines for industrial and marine applications, spare parts and special alloy castings.

Bharti Airtel gets approval for acquiring operations of Millicom in Rwanda
Bharti Airtel Ltd (Airtel) a leading global telecommunications services provider with operations in 16 countries across Asia and Africa, announced that it has received an approval for the acquisition of Tigo Rwanda Ltd (Tigo Rwanda), a subsidiary of Millicom International Cellular S.A. (Millicom) from the Rwanda Utilities Regulatory Authority (RURA).
The merged entity will have the largest customer base in Rwanda with 5.9 million subscribers. The combined networks of the two companies will serve customers with voice/ data services, global roaming and mobile banking services. It will also have Rwanda’s largest sales and distribution network.
The merger will result in the only negative ebitda OpCo joining other 13 positive ebitda OpCos in Africa.

Eveready to form JV with Indonesia based company for FMCG products
India’s leading dry cell battery maker, Eveready Industries India Limited (EIIL) will form a Joint Venture (JV) with Indonesia based Universal Wellbeing Pte. Ltd. (UW) for manufacturing, importing and marketing of Fast Moving Consumer Goods (FMCG) in India. EIIL will hold 30% stake in the soon-to-be-formed JV while UW will hold the remaining 70% stake. EIIL announced this to the stock exchanges on January 24, 2018.
EIIL plans to make use of its pan-India battery distribution network to sell a bouquet of FMCG products in urban and rural areas. As per its FY17 Annual Report, EIIL has a 4,000+ distribution network and 42 distribution centers. EIIL’s products are available across more than 3.2mn outlets.

Bank of Baroda may float $1bn QIP soon
Media reports suggest that Bank of Baroda is expected to float its $1bn qualified institutional placement of shares in two to three weeks. In November, The Finance Committee of the Board approved the proposal of raising additional equity capital aggregating up to Rs6, 000cr by way of a rights issue or qualified institutions placements (QIP). This move is positive for the bank, as it would provide much-needed headroom to provide for bad loans and would also help for next leg of loan growth. The stock would react positively to this news. Banks have been raising funds in the past few months to boost their capital adequacy ratio ahead of the government's recapitalization plan.


MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647